Aura Biosciences Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting
May 26 2022 - 5:26PM
Business Wire
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage
biotechnology company developing a novel class of virus-like drug
conjugate (VDC) therapies for multiple oncology indications, today
announced the publication of preclinical data on AU-011, its first
VDC product candidate, in combination with immune checkpoint
inhibitors. AU-011 is being developed for the treatment of
life-threatening cancers with high unmet need, including primary
choroidal melanoma and non-muscle invasive bladder cancer (NMIBC).
The abstract has been published online as part of the 2022 American
Society of Clinical Oncology (ASCO) Annual Meeting, being held June
3-7, 2022, in Chicago, IL.
“These data show that AU-011, a first in class VDC, in
combination with immune checkpoint inhibition is effective against
both primary tumors and distant metastases in a preclinical model,
demonstrating its clinical potential for the treatment of choroidal
melanoma and certain other cancers. This includes the potential to
treat both the primary tumor in early-stage disease and to treat
metastatic lesions, whether clinically present or not at initial
treatment.” “We are so appreciative of our collaboration with the
scientists and clinicians at Leiden University Medical Center in
The Netherlands, one of the top European clinical and research
centers in ocular oncology,” said Dr. Cadmus Rich, Chief Medical
officer and Head of R&D of Aura Biosciences.
“It is promising to see the results of these experiments, as we
have shown that in murine models, the previously observed positive
effects of AU-011 as a single agent could be enhanced with the
addition of immune checkpoint inhibitors,” said Dr. Martine Jager,
Professor of Ophthalmology at Leiden University. “In addition, we
show that not only the primary tumor, but also distant lesions, are
targeted. Our survival data in murine models show that the
combination of VDCs with immune checkpoint inhibitors is a
potential new treatment modality that may generate a potent
targeted cytotoxicity on local tumors as well as potential
metastases."
Abstract details:
Title: A novel Virus-Like-Drug Conjugate (VDC) in
combination with immune checkpoint inhibitors for the treatment of
primary tumors and distant metastasis Authors: Ruben Victor
Huis in 't Veld1, Sen Ma1, Rhonda Kines2, Anneli Savinainen2,
Cadmus Collins Rich2, Ferry Ossendorp3, Martine Jager1; 1Leiden
University Medical Center, Leiden, Netherlands; 2Aura Biosciences,
Cambridge, MA; 3Department of Immunology, Leiden University Medical
Center, Leiden, Netherlands Session Category: Publication -
2022 ASCO Annual Meeting Proceedings Session Title:
Developmental Therapeutics – Immunotherapy Abstract Number:
e14544 The published abstract is available here.
About Aura Biosciences
Aura Biosciences, Inc. is a clinical-stage biotechnology company
developing virus-like drug conjugates (VDCs), a novel class of
therapies, for the treatment of multiple oncology indications.
Aura’s lead VDC candidate, AU-011 (belzupacap sarotalocan),
consists of a virus-like particle conjugated with an anti-cancer
agent. AU-011 selectively targets and destroys cancer cells and
activates the immune system with the potential to create
long-lasting anti-tumor immunity. AU-011 is currently in
development for ocular cancers, with an ongoing Phase 2 dose
escalation clinical trial evaluating first-line treatment of
choroidal melanoma, a vision- and life-threatening form of eye
cancer where standard of care with radiotherapy leaves patients
with severe comorbidities, including major vision loss. Aura plans
to develop AU-011 across its ocular oncology franchise including
for the treatment of patients with choroidal metastases. In
addition, leveraging Aura’s technology platform, Aura is developing
AU-011 more broadly across multiple cancers, starting with a
planned Phase 1 clinical trial in patients with non-muscle invasive
bladder cancer. Aura is headquartered in Cambridge, MA.
For more information, visit aurabiosciences.com, or follow us on
Twitter and LinkedIn.
Forward Looking Statement
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, as amended, and other federal securities laws. Any statements
that are not statements of historical fact may be deemed to be
forward looking statements. Words such as “may,” “will,” “could”,
“should,” “expects,” “intends,” “plans,” “anticipates,” “believes,”
“estimates,” “predicts,” “projects,” “seeks,” “endeavor,”
“potential,” “continue” or the negative of such words or other
similar expressions that can be used to identify forward-looking
statements. These forward looking statements include express or
implied statements regarding Aura’s future expectations, plans and
prospects, including, without limitation, statements regarding the
therapeutic potential of AU-011 for the treatment of cancers
including choroidal melanoma and NMIBC and expectations with
respect to the clinical development of AU-011.
The forward-looking statements in this press release are neither
promises nor guarantees, and investors should not place undue
reliance on these forward-looking statements because they involve
known and unknown risks, uncertainties, and other factors, many of
which are beyond Aura’s control and which could cause actual
results to differ materially from those expressed or implied by
these forward-looking statements, including, without limitation,
uncertainties inherent in clinical trials and in the availability
and timing of data from ongoing clinical trials; the expected
timing for submissions for regulatory approval or review by
governmental authorities; the risk that the results of Aura’s
clinical trials may not be predictive of future results in
connection with future clinical trials; whether Aura will receive
regulatory approvals to conduct trials or to market products;
whether Aura’s cash resources will be sufficient to fund its
foreseeable and unforeseeable operating expenses and capital
expenditure requirements; risks, assumptions and uncertainties
regarding the impact of the continuing COVID-19 pandemic on Aura’s
business, operations, strategy, goals and anticipated timelines;
Aura’s ongoing and planned pre-clinical activities; and Aura’s
ability to initiate, enroll, conduct or complete ongoing and
planned clinical trials. These risks, uncertainties, and other
factors include those risks and uncertainties described under the
heading “Risk Factors” in Aura’s Quarterly Report on Form 10-Q for
the quarter ended March 31, 2022 filed with the U.S. Securities and
Exchange Commission (SEC) and in subsequent filings made by Aura
with the SEC, which are available on the SEC’s website at
www.sec.gov. Except as required by law, Aura disclaims any
intention or responsibility for updating or revising any
forward-looking statements contained in this press release in the
event of new information, future developments or otherwise. These
forward-looking statements are based on Aura’s current expectations
and speak only as of the date hereof and no representations or
warranties (express or implied) are made about the accuracy of any
such forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220526005604/en/
Investor and Media Contact: Matthew DeYoung Argot
Partners 212-600-1902 | aura@argotpartners.com
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Aura Biosciences (NASDAQ:AURA)
Historical Stock Chart
From Apr 2023 to Apr 2024